# ACHV — Achieve Life Sciences Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ACHV  
**Sources:** 20  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-achv-achieve-life-sciences-inc-catalysts-narrative-risks-5813

---

# Achieve Life Sciences Inc. (Nasdaq: ACHV) — Point-in-Time Overview (as of 2026-10-03)

## Company Profile
Achieve Life Sciences is a late-stage specialty pharmaceutical company developing **cytisinicline**, a plant-based alkaloid for nicotine dependence treatment (smoking and e-cigarette cessation) [[2]](https://achievelifesciences.com/achieve-to-present-52-week-cytisinicline-efficacy-data-for-smoking-and-e-cigarette-cessation-at-chest-2026/). The company is pre-revenue with no marketed product, and is a $685 million-market-cap biotech [[6]](https://www.ainvest.com/news/achv-chest-2026-efficacy-data-confirmatory-real-bet-manufacturing-fix-unpriced-vaping-indication-2609/), [[7]](https://www.msn.com/en-us/money/general/achieve-life-sciences-stock-has-nearly-tripled-in-the-last-year-now-it-just-needs-to-turn-a-profit/ar-AA29XPLJ).

## Recent Catalysts (Last ~1–3 Months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-achv-achieve-life-sciences-inc-catalysts-narrative-risks-5813 (free to sign up)._
